NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive(R) to Host Investor Morning on November 14, 2013

SAN DIEGO, CA -- (Marketwired) -- 11/04/13 -- NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that it will host a meeting for investors and analysts at its NuVasive East office, 117 West Century Road, Paramus, NJ, 07652, on Thursday, November 14, 2013 from 8:30 a.m. to 11:00 a.m. ET.

Registration and breakfast will commence at 8:00 a.m., followed by a formal presentation beginning at 8:30 a.m. Several senior members of the executive team will provide an in-depth progress report on the top drivers of the Company's strategy for sustained growth with increasing profitability. Executive management in attendance will include:

  • Alex Lukianov, Chairman and Chief Executive Officer
  • Keith Valentine, President and Chief Operating Officer
  • Patrick Miles, President of Global Products and Services
  • Matt Link, Executive Vice President of US Sales
  • Michael Lambert, Executive Vice President and Chief Financial Officer
  • Russell Powers, Executive Vice President of International
  • Craig Hunsaker, Senior Vice President of Global Human Resources
  • Quentin Blackford, Senior Vice President of Finance and Investor Relations

The audience will have an opportunity to learn more about the innovation featured at both EuroSpine and NASS. There will be ample time for Q&A.

A live webcast of the meeting and the presentation will be accessible online from the investor relations page of the Company's corporate website at
To RSVP for the event, please contact

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.

NuVasive offers a comprehensive spine portfolio of over 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-Up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties are described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Investor Contact:
Tina Jacobsen
NuVasive, Inc.
Email Contact

Media Contact:
Nicole Collins
NuVasive, Inc.
Email Contact

Source: NuVasive, Inc.